2026 Q2 -tulosraportti
8 päivää sitten
‧33 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 12.8. | ||
2026 Q1 -tulosraportti 12.5. | ||
2025 Q4 -tulosraportti 17.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14.7. · Muokattuhttps://finance.yahoo.com/healthcare/articles/icecure-expands-u-commercial-team-123200784.html The company has just announced a significant expansion of their US sales and marketing team. This comes as a direct response to an explosively growing demand for their flagship product, the ProSense® system, for the treatment of early-stage breast cancer. What is the background for the news? 70% growth in the USA: IceCure recently announced that their active commercial installed base in the USA has grown by a full 70%. This growth was triggered by them receiving crucial FDA approval in October 2025 to treat low-risk, early-stage breast cancer in women over 70 years old. Geographical expansion: To meet demand, the company has hired dedicated sales and marketing staff in key regions such as New York, Southern California, and the Midwest. ProSense procedures are now performed in major metropolitan areas like Los Angeles, Detroit, Dallas, and Atlanta. What does this mean for you as an investor? If you look at IceCure through investor glasses, there are three crucial things to take away from this expansion: 1. The company shifts gears from "development" to "commercial execution" For many years, IceCure has been a case about clinical studies (such as the large ICE-3 study) and waiting for FDA. Now the approval is in, and the company shows action by building the sales infrastructure needed to convert clinical success into hard dollars. 2. The "Razor and Blade" model begins to roll: IceCure operates on a business model where they sell both the machine (ProSense) and the disposable needles (probes) used for every freeze treatment. More salespeople in the field -> More installed machines -> A rapidly increasing and recurring sale of disposable needles with high margins. 3. The Risk: Increased "Burn Rate" in the short term When expanding its sales team, the company's operating costs (SG&A) immediately increase, while revenues from increased sales typically lag a bit (because the sales cycle in hospitals can take 3-9 months). As an investor, you should keep an eye on their cash reserves (they had approx. 8.1 million USD in cash at the end of Q1 2026) to ensure they have enough money to finance this growth phase without further diluting shareholders in the near future. Overall assessment: This is a classic "growth news". It confirms that there is real, organic demand in the US market for an alternative to traditional breast surgery (lumpectomy). It costs money to make money, and IceCure is now stepping on the gas in the USA to quickly gain market share. 🤞🤝
·25.6.Most things seem to point in the right direction, competent management, great potential for the product, analysts who are unequivocally positive and high price targets. These are shares at a cheap price now. There is also a high probability that the application in Japan will go through, as Terumo is responsible for the application.- ·25.6. · MuokattuWhy is this important for IceCure? Retains large investors: Many investment funds and institutional investors have rules that they are not allowed to own shares that cost under 1 dollar, or shares that are traded on the unregulated "penny stock" markets. By remaining on Nasdaq, IceCure maintains access to the big money. Peace of mind: Management has now averted a potential crisis. Instead of having to spend energy on panic solutions (such as a reverse stock split, where shares are merged to artificially pump up the price), they can now focus 100% on their business – such as the upcoming approval process in Japan, which you read about in the other news. Sign of confidence: That the share price has climbed back above 1 dollar by its own strength often shows that the market and investors have gained greater faith in the company's future, potentially aided by good clinical news. Important! 🙏
- ·23.6.https://finance.yahoo.com/healthcare/articles/icecure-highlights-peer-reviewed-journal-121000775.html The medical journal International Journal of Surgery has published an independent study that endorses IceCure's freezing technology (cryoablation) as a fully viable, gentle alternative to traditional breast cancer surgery. The three most important points are: Better than heat treatment: The study establishes that freezing is far less painful for the patient than heat treatment (RFA), and that the doctor can better control precision via ultrasound during the procedure. Excellent results: The technique (where the tumor is frozen away through a thin needle) provides the same high safety as surgery, but with minimal scars and shorter treatment time. Important boost in Japan: The results are based on data from leading Japanese doctors. This gives IceCure and their Japanese partner, Terumo, strong scientific backing towards their expected application for market approval in Japan in the second half of 2026. 🙏🤞🤌
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
8 päivää sitten
‧33 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14.7. · Muokattuhttps://finance.yahoo.com/healthcare/articles/icecure-expands-u-commercial-team-123200784.html The company has just announced a significant expansion of their US sales and marketing team. This comes as a direct response to an explosively growing demand for their flagship product, the ProSense® system, for the treatment of early-stage breast cancer. What is the background for the news? 70% growth in the USA: IceCure recently announced that their active commercial installed base in the USA has grown by a full 70%. This growth was triggered by them receiving crucial FDA approval in October 2025 to treat low-risk, early-stage breast cancer in women over 70 years old. Geographical expansion: To meet demand, the company has hired dedicated sales and marketing staff in key regions such as New York, Southern California, and the Midwest. ProSense procedures are now performed in major metropolitan areas like Los Angeles, Detroit, Dallas, and Atlanta. What does this mean for you as an investor? If you look at IceCure through investor glasses, there are three crucial things to take away from this expansion: 1. The company shifts gears from "development" to "commercial execution" For many years, IceCure has been a case about clinical studies (such as the large ICE-3 study) and waiting for FDA. Now the approval is in, and the company shows action by building the sales infrastructure needed to convert clinical success into hard dollars. 2. The "Razor and Blade" model begins to roll: IceCure operates on a business model where they sell both the machine (ProSense) and the disposable needles (probes) used for every freeze treatment. More salespeople in the field -> More installed machines -> A rapidly increasing and recurring sale of disposable needles with high margins. 3. The Risk: Increased "Burn Rate" in the short term When expanding its sales team, the company's operating costs (SG&A) immediately increase, while revenues from increased sales typically lag a bit (because the sales cycle in hospitals can take 3-9 months). As an investor, you should keep an eye on their cash reserves (they had approx. 8.1 million USD in cash at the end of Q1 2026) to ensure they have enough money to finance this growth phase without further diluting shareholders in the near future. Overall assessment: This is a classic "growth news". It confirms that there is real, organic demand in the US market for an alternative to traditional breast surgery (lumpectomy). It costs money to make money, and IceCure is now stepping on the gas in the USA to quickly gain market share. 🤞🤝
- ·25.6.Most things seem to point in the right direction, competent management, great potential for the product, analysts who are unequivocally positive and high price targets. These are shares at a cheap price now. There is also a high probability that the application in Japan will go through, as Terumo is responsible for the application.
- ·25.6. · MuokattuWhy is this important for IceCure? Retains large investors: Many investment funds and institutional investors have rules that they are not allowed to own shares that cost under 1 dollar, or shares that are traded on the unregulated "penny stock" markets. By remaining on Nasdaq, IceCure maintains access to the big money. Peace of mind: Management has now averted a potential crisis. Instead of having to spend energy on panic solutions (such as a reverse stock split, where shares are merged to artificially pump up the price), they can now focus 100% on their business – such as the upcoming approval process in Japan, which you read about in the other news. Sign of confidence: That the share price has climbed back above 1 dollar by its own strength often shows that the market and investors have gained greater faith in the company's future, potentially aided by good clinical news. Important! 🙏
- ·23.6.https://finance.yahoo.com/healthcare/articles/icecure-highlights-peer-reviewed-journal-121000775.html The medical journal International Journal of Surgery has published an independent study that endorses IceCure's freezing technology (cryoablation) as a fully viable, gentle alternative to traditional breast cancer surgery. The three most important points are: Better than heat treatment: The study establishes that freezing is far less painful for the patient than heat treatment (RFA), and that the doctor can better control precision via ultrasound during the procedure. Excellent results: The technique (where the tumor is frozen away through a thin needle) provides the same high safety as surgery, but with minimal scars and shorter treatment time. Important boost in Japan: The results are based on data from leading Japanese doctors. This gives IceCure and their Japanese partner, Terumo, strong scientific backing towards their expected application for market approval in Japan in the second half of 2026. 🙏🤞🤌
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 12.8. | ||
2026 Q1 -tulosraportti 12.5. | ||
2025 Q4 -tulosraportti 17.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 |
2026 Q2 -tulosraportti
8 päivää sitten
‧33 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 12.8. | ||
2026 Q1 -tulosraportti 12.5. | ||
2025 Q4 -tulosraportti 17.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14.7. · Muokattuhttps://finance.yahoo.com/healthcare/articles/icecure-expands-u-commercial-team-123200784.html The company has just announced a significant expansion of their US sales and marketing team. This comes as a direct response to an explosively growing demand for their flagship product, the ProSense® system, for the treatment of early-stage breast cancer. What is the background for the news? 70% growth in the USA: IceCure recently announced that their active commercial installed base in the USA has grown by a full 70%. This growth was triggered by them receiving crucial FDA approval in October 2025 to treat low-risk, early-stage breast cancer in women over 70 years old. Geographical expansion: To meet demand, the company has hired dedicated sales and marketing staff in key regions such as New York, Southern California, and the Midwest. ProSense procedures are now performed in major metropolitan areas like Los Angeles, Detroit, Dallas, and Atlanta. What does this mean for you as an investor? If you look at IceCure through investor glasses, there are three crucial things to take away from this expansion: 1. The company shifts gears from "development" to "commercial execution" For many years, IceCure has been a case about clinical studies (such as the large ICE-3 study) and waiting for FDA. Now the approval is in, and the company shows action by building the sales infrastructure needed to convert clinical success into hard dollars. 2. The "Razor and Blade" model begins to roll: IceCure operates on a business model where they sell both the machine (ProSense) and the disposable needles (probes) used for every freeze treatment. More salespeople in the field -> More installed machines -> A rapidly increasing and recurring sale of disposable needles with high margins. 3. The Risk: Increased "Burn Rate" in the short term When expanding its sales team, the company's operating costs (SG&A) immediately increase, while revenues from increased sales typically lag a bit (because the sales cycle in hospitals can take 3-9 months). As an investor, you should keep an eye on their cash reserves (they had approx. 8.1 million USD in cash at the end of Q1 2026) to ensure they have enough money to finance this growth phase without further diluting shareholders in the near future. Overall assessment: This is a classic "growth news". It confirms that there is real, organic demand in the US market for an alternative to traditional breast surgery (lumpectomy). It costs money to make money, and IceCure is now stepping on the gas in the USA to quickly gain market share. 🤞🤝
- ·25.6.Most things seem to point in the right direction, competent management, great potential for the product, analysts who are unequivocally positive and high price targets. These are shares at a cheap price now. There is also a high probability that the application in Japan will go through, as Terumo is responsible for the application.
- ·25.6. · MuokattuWhy is this important for IceCure? Retains large investors: Many investment funds and institutional investors have rules that they are not allowed to own shares that cost under 1 dollar, or shares that are traded on the unregulated "penny stock" markets. By remaining on Nasdaq, IceCure maintains access to the big money. Peace of mind: Management has now averted a potential crisis. Instead of having to spend energy on panic solutions (such as a reverse stock split, where shares are merged to artificially pump up the price), they can now focus 100% on their business – such as the upcoming approval process in Japan, which you read about in the other news. Sign of confidence: That the share price has climbed back above 1 dollar by its own strength often shows that the market and investors have gained greater faith in the company's future, potentially aided by good clinical news. Important! 🙏
- ·23.6.https://finance.yahoo.com/healthcare/articles/icecure-highlights-peer-reviewed-journal-121000775.html The medical journal International Journal of Surgery has published an independent study that endorses IceCure's freezing technology (cryoablation) as a fully viable, gentle alternative to traditional breast cancer surgery. The three most important points are: Better than heat treatment: The study establishes that freezing is far less painful for the patient than heat treatment (RFA), and that the doctor can better control precision via ultrasound during the procedure. Excellent results: The technique (where the tumor is frozen away through a thin needle) provides the same high safety as surgery, but with minimal scars and shorter treatment time. Important boost in Japan: The results are based on data from leading Japanese doctors. This gives IceCure and their Japanese partner, Terumo, strong scientific backing towards their expected application for market approval in Japan in the second half of 2026. 🙏🤞🤌
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt